Prem Kapur

653 total citations
47 papers, 403 citations indexed

About

Prem Kapur is a scholar working on Epidemiology, Infectious Diseases and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Prem Kapur has authored 47 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 10 papers in Infectious Diseases and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Prem Kapur's work include Pharmaceutical Practices and Patient Outcomes (7 papers), Tuberculosis Research and Epidemiology (6 papers) and Pharmacovigilance and Adverse Drug Reactions (6 papers). Prem Kapur is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (7 papers), Tuberculosis Research and Epidemiology (6 papers) and Pharmacovigilance and Adverse Drug Reactions (6 papers). Prem Kapur collaborates with scholars based in India, Pakistan and Saudi Arabia. Prem Kapur's co-authors include Mohd. Aqil, Krishna Kolappa Pillai, KK Pillai, Manju Sharma, Pinaki Ghosh, Mohammad Adil, Nidhi Agarwal, K.K. Pillai, M. S. Alam and Ayan Kumar Das and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Metabolism.

In The Last Decade

Prem Kapur

45 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prem Kapur India 12 107 87 61 49 46 47 403
Mukta N. Chowta India 12 56 0.5× 57 0.7× 66 1.1× 33 0.7× 75 1.6× 58 422
Vijay Khajuria India 11 49 0.5× 38 0.4× 42 0.7× 117 2.4× 34 0.7× 71 529
Yet Hoi Hong Malaysia 13 51 0.5× 64 0.7× 91 1.5× 19 0.4× 50 1.1× 22 477
V. Marešová Czechia 10 70 0.7× 53 0.6× 32 0.5× 22 0.4× 29 0.6× 20 412
Ettore Marconi Italy 11 19 0.2× 107 1.2× 50 0.8× 22 0.4× 33 0.7× 50 383
Melony Fortuin-de Smidt South Africa 10 24 0.2× 79 0.9× 35 0.6× 43 0.9× 71 1.5× 18 311
Vincent H Mabasa Canada 14 45 0.4× 114 1.3× 66 1.1× 7 0.1× 34 0.7× 27 603
Hailong Li China 13 22 0.2× 62 0.7× 16 0.3× 30 0.6× 20 0.4× 48 389
Hadeel Alkofide Saudi Arabia 12 44 0.4× 40 0.5× 97 1.6× 6 0.1× 49 1.1× 50 449
Alphienes Stanley Xavier India 12 22 0.2× 130 1.5× 31 0.5× 51 1.0× 141 3.1× 24 518

Countries citing papers authored by Prem Kapur

Since Specialization
Citations

This map shows the geographic impact of Prem Kapur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prem Kapur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prem Kapur more than expected).

Fields of papers citing papers by Prem Kapur

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prem Kapur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prem Kapur. The network helps show where Prem Kapur may publish in the future.

Co-authorship network of co-authors of Prem Kapur

This figure shows the co-authorship network connecting the top 25 collaborators of Prem Kapur. A scholar is included among the top collaborators of Prem Kapur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prem Kapur. Prem Kapur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pathak, M.A., et al.. (2024). Effect of sodium-glucose Co-transporter 2 inhibitors on MCP-1 and uromodulin levels in patients with type 2 diabetes mellitus. Clinical Epidemiology and Global Health. 31. 101888–101888. 2 indexed citations
2.
Kapur, Prem, et al.. (2021). Elevated urinary IL-36α and IL-18 levels are associated with diabetic nephropathy in patients with type 2 diabetes mellitus. Minerva Endocrinology. 46(2). 226–232. 6 indexed citations
3.
Quadir, Neha, Syed Asad Rahman, Javeed Ahmad, et al.. (2021). Development and Validation of Signature Sequence–Based PCR for Improved Molecular Diagnosis of Tuberculosis. Journal of Molecular Diagnostics. 23(9). 1138–1144. 5 indexed citations
4.
5.
Agarwal, Nidhi, et al.. (2021). Evaluation of Stress and Associated Biochemical Changes in Patients with Type 2 Diabetes Mellitus and Obesity. Diabetes Metabolic Syndrome and Obesity. Volume 14. 705–717. 8 indexed citations
6.
7.
Siddiqui, Ali Nasir, et al.. (2020). Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing. Tuberculosis. 120. 101902–101902. 14 indexed citations
8.
Singh, Pooja, Saumya Singh, Naresh Arora, et al.. (2019). SeeTB: A novel alternative to sputum smear microscopy to diagnose tuberculosis in high burden countries. Scientific Reports. 9(1). 16371–16371. 11 indexed citations
9.
Agarwal, Nidhi, et al.. (2019). <p>Factors Influencing Participation Of Healthy Volunteers In Clinical Trials: Findings From A Cross-Sectional Study In Delhi, North India</p>. Patient Preference and Adherence. Volume 13. 2007–2015. 6 indexed citations
10.
Kapur, Prem, et al.. (2019). <p>Attenuated serum 25-hydroxyvitamin D and vitamin D binding protein associated with cognitive impairment in patients with type 2 diabetes</p>. Diabetes Metabolic Syndrome and Obesity. Volume 12. 1763–1772. 9 indexed citations
11.
Agarwal, Nidhi, et al.. (2019). Study of Awareness and Practice of Informed Consent Process Among Clinical Trial Participants and Their Motives Behind Participation. Asia Pacific Journal of Public Health. 31(8). 710–718. 2 indexed citations
12.
Khan, Rashid Ali, et al.. (2017). Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. Therapeutics and Clinical Risk Management. Volume 13. 139–149. 29 indexed citations
13.
Pillai, Krishna Kolappa, et al.. (2017). Adverse drug reaction monitoring during antimicrobial therapy for septicemia patients at a university hospital in New Delhi. The Korean Journal of Internal Medicine. 33(6). 1203–1209. 10 indexed citations
14.
Kapur, Prem, et al.. (2014). Antimicrobial Sensitivity Pattern of Bacterial Pathogens in Urinary Tract Infections in South Delhi, India. Reviews on Recent Clinical Trials. 9(4). 271–275. 8 indexed citations
15.
Kapur, Prem, Ayan Kumar Das, & Mridu Dudeja. (2014). Balantidium Coli liver abscess: first case report from India. Journal of Parasitic Diseases. 40(1). 138–140. 17 indexed citations
16.
Khurshid, Fowad, et al.. (2012). Monitoring of adverse drug reactions associated with antihypertensive medicines at a university teaching hospital in New Delhi. DARU Journal of Pharmaceutical Sciences. 20(1). 34–34. 16 indexed citations
17.
Kapur, Prem, et al.. (2010). Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. Journal of Clinical Pharmacy and Therapeutics. 35(3). 267–277. 42 indexed citations
18.
Aqil, Mohd., et al.. (2010). A pharmacovigilance study on patients of bronchial asthma in a teaching hospital. Journal of Pharmacy And Bioallied Sciences. 2(4). 333–333. 10 indexed citations
19.
Aqil, Mohd., et al.. (2009). A pharmacovigilance study of antihypertensive medicines at a South Delhi hospital. Indian Journal of Pharmaceutical Sciences. 71(3). 338–338. 12 indexed citations
20.
Sharma, Himanshu, et al.. (2007). A pharmacovigilance study in the department of medicine of a university teaching hospital. Pharmacy Practice. 5(1). 46–9. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mukta N. Chowta Breakdown of academic impact, for papers by Vijay Khajuria Breakdown of academic impact, for papers by Yet Hoi Hong Breakdown of academic impact, for papers by V. Marešová Breakdown of academic impact, for papers by Ettore Marconi Breakdown of academic impact, for papers by Melony Fortuin-de Smidt Breakdown of academic impact, for papers by Vincent H Mabasa Breakdown of academic impact, for papers by Hailong Li Breakdown of academic impact, for papers by Hadeel Alkofide Breakdown of academic impact, for papers by Alphienes Stanley Xavier
Rankless by CCL
2026